Triantos Christos, Kalafateli Maria, Spantidea Panagiota I, Goukos Dimitrios, Koutroumpakis Efstratios, Konstantakis Christos, Assimakopoulos Stelios F, Gogos Charalambos, Mouzaki Athanasia, Daikos Georgios, Thomopoulos Konstantinos
Department of Gastroenterology, University Hospital of Patras (Christos Triantos, Maria Kalafateli, Efstratios Koutroumpakis, Christos Konstantakis, Konstantinos Thomopoulos).
Division of Hematology, Department of Internal Medicine, Medical School, University of Patras (Panagiota Spadidea, Athanasia Mouzaki).
Ann Gastroenterol. 2017;30(4):450-456. doi: 10.20524/aog.2017.0142. Epub 2017 Apr 6.
The aim of this study was to explore the presence of bacterial products and the cytokine profile in outpatients with cirrhosis before and after short-term (4-8 weeks) administration of proton pump inhibitors (PPIs).
Seventeen patients with cirrhosis-male/female: 12/5; age: median 59.2 years (49-65); etiology: HBV±HDV 23.5%, HCV 17.7%, alcohol 41.2%, other 17.6%; Child-Pugh score: median 7.5 (5-12); Model for End-stage Liver Disease: 10.5 (7-21); ascites (%): 3 (17.7)-attending the outpatient clinics were included. None had hepatocellular carcinoma. Indications for PPIs were: esophagitis (n=6, 35.3%), peptic ulcer (n=10, 58.6%) and other (n=1, 5.9%). Bacterial DNA in serum and the levels of endotoxin, lipopolysaccharide binding protein, transforming growth factor-β, interleukin -1β, -6, -8, -12, -10, tumor necrosis factor-α and nitric oxide were assessed at baseline (time 1) and at the end of treatment (time 2). The Wilcoxon signed rank test was used to evaluate significant differences in the parameters assayed before and after PPI administration.
No patients developed infection during the study period. Bacterial DNA was not detected before or after treatment. No significant differences were observed between the concentrations of any indices between times 1 and 2 (P>0.05). Subgroup analysis according to Child-Pugh stage yielded similar results.
Short-term administration of PPIs had no effect on bacterial DNA, bacterial products or cytokine concentrations in patients with liver cirrhosis.
本研究旨在探讨短期(4 - 8周)服用质子泵抑制剂(PPI)前后肝硬化门诊患者体内细菌产物的存在情况及细胞因子谱。
纳入17例肝硬化门诊患者,男/女比例为12/5;年龄:中位数59.2岁(49 - 65岁);病因:乙肝±丁肝23.5%,丙肝17.7%,酒精性41.2%,其他17.6%;Child-Pugh评分:中位数7.5(5 - 12);终末期肝病模型评分:10.5(7 - 21);腹水(%):3(17.7)。均无肝细胞癌。使用PPI的指征为:食管炎(n = 6,35.3%)、消化性溃疡(n = 10,58.6%)及其他(n = 1,5.9%)。在基线(时间1)和治疗结束时(时间2)评估血清中的细菌DNA以及内毒素、脂多糖结合蛋白、转化生长因子-β、白细胞介素-1β、-6、-8、-12、-10、肿瘤坏死因子-α和一氧化氮的水平。采用Wilcoxon符号秩检验评估PPI给药前后所测参数的显著差异。
研究期间无患者发生感染。治疗前后均未检测到细菌DNA。时间1和时间2之间任何指标的浓度均未观察到显著差异(P>0.05)。根据Child-Pugh分期进行的亚组分析得出类似结果。
短期服用PPI对肝硬化患者的细菌DNA、细菌产物或细胞因子浓度无影响。